Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Therapeutics, Agilent, Evident Technologies, Spotfire

Premium

ExonHit Therapeutics last week added Nuclear Receptor and Co-Regulator arrays to its SpliceArray Service business unit. Launched in February, the SpliceArray Service provides users with ExonHit's splice variant content, probe design, and customized analysis with Agilent's microarray platform.

The Paris -based firm said that the global pharmaceutical market for drugs targeting nuclear receptors is estimated to be around $40 billion and the new arrays will aid in drug discovery. The initial rollout of the service included Ion-Channel and GPCR arrays.


Evident Technologies last week released its second-generation Type 2 EviTag luminescent label. The Troy, NY-based company claims the T2 EviTag provides increased flexibility, wider applications and testing cost reduction in bioassays and other types of life science research.

Evident's EviTag technology incorporates the company's EviDot quantum dots, which are semiconductor nanocrystals coated with a variety of patented, water-stabilizing surface treatments. The new product complements Evident's Type 1 EviTags which the company markets as a fluorescent label.


Spotfire last month launched DecisionSite 8.1, the latest version of its visual data analytics platform. The company claims the newer version of DecisionSite offers user greater analysis across the R&D organization through faster, more flexible data access; enhanced data analysis features; expanded results-sharing capabilities; and improved security and administration.